Kondru RK - Search Results

1

A Tool for Predicting Regulatory Approval After Phase II Testing of New Oncology Compounds.

DiMasi JA, Hermann JC, Twyman K, Kondru RK, Stergiopoulos S, Getz KA, Rackoff W. DiMasi JA, et al. Among authors: kondru rk. Clin Pharmacol Ther. 2015 Nov;98(5):506-13. doi: 10.1002/cpt.194. Epub 2015 Sep 24. Clin Pharmacol Ther. 2015. PMID: 26239772

2

Finding the perfect spot for fluorine: improving potency up to 40-fold during a rational fluorine scan of a Bruton's Tyrosine Kinase (BTK) inhibitor scaffold.

Lou Y, Sweeney ZK, Kuglstatter A, Davis D, Goldstein DM, Han X, Hong J, Kocer B, Kondru RK, Litman R, McIntosh J, Sarma K, Suh J, Taygerly J, Owens TD. Lou Y, et al. Among authors: kondru rk. Bioorg Med Chem Lett. 2015 Jan 15;25(2):367-71. doi: 10.1016/j.bmcl.2014.11.030. Epub 2014 Nov 20. Bioorg Med Chem Lett. 2015. PMID: 25466710

3

Structure-based drug design of RN486, a potent and selective Bruton's tyrosine kinase (BTK) inhibitor, for the treatment of rheumatoid arthritis.

Lou Y, Han X, Kuglstatter A, Kondru RK, Sweeney ZK, Soth M, McIntosh J, Litman R, Suh J, Kocer B, Davis D, Park J, Frauchiger S, Dewdney N, Zecic H, Taygerly JP, Sarma K, Hong J, Hill RJ, Gabriel T, Goldstein DM, Owens TD. Lou Y, et al. Among authors: kondru rk. J Med Chem. 2015 Jan 8;58(1):512-6. doi: 10.1021/jm500305p. Epub 2014 Apr 16. J Med Chem. 2015. PMID: 24712864

4

Bruton's tyrosine kinase inhibitors: approaches to potent and selective inhibition, preclinical and clinical evaluation for inflammatory diseases and B cell malignancies.

Lou Y, Owens TD, Kuglstatter A, Kondru RK, Goldstein DM. Lou Y, et al. Among authors: kondru rk. J Med Chem. 2012 May 24;55(10):4539-50. doi: 10.1021/jm300035p. Epub 2012 Mar 21. J Med Chem. 2012. PMID: 22394077 Review. No abstract available.

5

Kinetic and thermodynamic assessment of binding of serotonin transporter inhibitors.

Martin RS, Henningsen RA, Suen A, Apparsundaram S, Leung B, Jia Z, Kondru RK, Milla ME. Martin RS, et al. Among authors: kondru rk. J Pharmacol Exp Ther. 2008 Dec;327(3):991-1000. doi: 10.1124/jpet.108.142307. Epub 2008 Sep 18. J Pharmacol Exp Ther. 2008. PMID: 18801948

6

Hepatitis C virus NS5B polymerase: QM/MM calculations show the important role of the internal energy in ligand binding.

Parks JM, Kondru RK, Hu H, Beratan DN, Yang W. Parks JM, et al. Among authors: kondru rk. J Phys Chem B. 2008 Mar 13;112(10):3168-76. doi: 10.1021/jp076885j. Epub 2008 Feb 14. J Phys Chem B. 2008. PMID: 18271573

7

Determining absolute configuration in flexible molecules: a case study.

Specht KM, Nam J, Ho DM, Berova N, Kondru RK, Beratan DN, Wipf P, Pascal RA Jr, Kahne D. Specht KM, et al. Among authors: kondru rk. J Am Chem Soc. 2001 Sep 19;123(37):8961-6. doi: 10.1021/ja0104406. J Am Chem Soc. 2001. PMID: 11552802

8

Chiral action at a distance: remote substituent effects on the optical activity of calyculins A and B.

Kondru RK, Beratan DN, Friestad GK, Smith AB 3rd, Wipf P. Kondru RK, et al. Org Lett. 2000 Jun 1;2(11):1509-12. doi: 10.1021/ol005634p. Org Lett. 2000. PMID: 10841466

9

Atomic contributions to the optical rotation angle as a quantitative probe of molecular chirality.

Kondru RK, Wipf P, Beratan DN. Kondru RK, et al. Science. 1998 Dec 18;282(5397):2247-50. doi: 10.1126/science.282.5397.2247. Science. 1998. PMID: 9856945

10

Synthetic and model computational studies of molar rotation additivity for interacting chiral centers: a reinvestigation of van't Hoff's principle.

Kondru RK, Lim S, Wipf P, Beratan DN. Kondru RK, et al. Chirality. 1997;9(5-6):469-77. doi: 10.1002/(SICI)1520-636X(1997)9:5/6<469::AID-CHIR13>3.0.CO;2-M. Chirality. 1997. PMID: 9329177

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

10 results

Search Page